{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:53:32Z","timestamp":1762271612329},"reference-count":91,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p>Relapsing ocular involvement is one of the major manifestations in Beh\u00e7et disease (BD). When ocular BD is left untreated, it often results in blindness in &lt;5\u2003years. Combining systemic corticosteroids with cyclosporine A and other conventional immune modulating agents has been the only choice for treatment. More recently, the introduction of \u2018<jats:italic>biologics\u2019<\/jats:italic> seems to be an effective therapy in patients affected with BD, especially in those with ocular disease. Our purpose was to survey the current knowledge regarding the biological therapeutic approaches for Beh\u00e7et uveitis. We focused on the most commonly used biological agents: \u2018<jats:italic>tumor necrosis factor\u2010alpha antagonists\u2019<\/jats:italic> and \u2018<jats:italic>interferon alpha\u2019.<\/jats:italic> We attempted to compare the effectiveness of these two biologicals and tried to balance on the pros and cons of these agents in clinical practice. The impressive efficacy of both approaches in sight\u2010threatening BD argues for their expanding role. Earlier introduction of these agents in the course of disease may prevent irreversible structural damage and may result in improved long\u2010term prognosis.<\/jats:p>","DOI":"10.1111\/j.1755-3768.2011.02348.x","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T17:49:28Z","timestamp":1334944168000},"page":"297-306","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Light on the Horizont: biologicals in Beh\u00e7et uveitis"],"prefix":"10.1111","volume":"91","author":[{"given":"Dicle","family":"Hazirolan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"St\u00fcbiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,20]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-006-9006-9"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-010-9357-0"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.4.467"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1590"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342607"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.101550"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/11588500-000000000-00000"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.09.002"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27581"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.1064"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_52"},{"key":"e_1_2_4_14_1","first-page":"S65","article-title":"Infliximab treatment\u2010induced formation of autoantibodies is common in Beh\u00e7et\u2019s disease","volume":"25","author":"Elezoglou A","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11301"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.04.009"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890340212"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163"},{"key":"e_1_2_4_19_1","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab","volume":"120","author":"Foroozan R","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.04.038"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.029"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1213-z"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.637"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.08.038"},{"issue":"24","key":"e_1_2_4_25_1","first-page":"S6","article-title":"Behcet\u2019s disease: an update on the pathogenesis","volume":"19","author":"Gul A","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_26_1","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome","volume":"21","author":"Hamuryudan V","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_4_27_1","first-page":"928","article-title":"Interferon alfa combined with azathioprine for the uveitis of Behcet\u2019s disease: an open study","volume":"4","author":"Hamuryudan V","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.010975"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21209"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024737"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-010-0859-0"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00659-0"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.06.019"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1491-6"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48382-3_111"},{"key":"e_1_2_4_36_1","first-page":"309","article-title":"Retinal complications during interferon therapy for chronic hepatitis C","volume":"91","author":"Kawano T","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/09286580701585892"},{"key":"e_1_2_4_39_1","first-page":"S8","article-title":"Safety of biologic therapies. An update","volume":"32","author":"Keystone EC","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313546"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.123554"},{"key":"e_1_2_4_42_1","first-page":"92","article-title":"Therapy of Beh\u00e7et\u2019s disease","volume":"5","author":"K\u00f6tter I","year":"1996","journal-title":"Ger J Ophthalmol"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.5.488"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.4.423"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.09.010"},{"key":"e_1_2_4_46_1","first-page":"1633","article-title":"Interferon\u2010a (IFN\u2010a) application versus tumor necrosis factor\u2010\u03b1 antagonism for ocular Behcet\u2019s disease: focusing more on IFN","volume":"32","author":"K\u00f6tter I","year":"2005","journal-title":"J Rheumatol"},{"issue":"4","key":"e_1_2_4_47_1","first-page":"S20","article-title":"Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet\u2019s disease treated with human recombinant interferon\u2010alpha2a. Results of an open study and review of the literature","volume":"23","author":"K\u00f6tter I","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_48_1","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades\u2010Behcet\u2019s disease treated with interferon\u2010alpha\u20102a","volume":"35","author":"Krause L","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2011.23.2.239"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22918"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem101"},{"key":"e_1_2_4_55_1","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno S","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1076\/0927-3948(200006)8:2;1-0;FT085"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3"},{"key":"e_1_2_4_58_1","first-page":"355","article-title":"Arterial and venous thromboembolic events during anti\u2010TNF therapy: a study of 85 spontaneous reports in the period 2000\u20132006","volume":"19","author":"Petitpain N","year":"2009","journal-title":"Biomed Mater Eng"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0058"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.03.050"},{"key":"e_1_2_4_61_1","first-page":"587","article-title":"Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha\u20102a","volume":"132","author":"Preziati D","year":"1995","journal-title":"Eur J Ophthalmol"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20712"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.10.003"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050541"},{"key":"e_1_2_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.4.473"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6"},{"key":"e_1_2_4_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_4_68_1","first-page":"181","article-title":"Successful treatment of long\u2010standing neuro\u2010Beh\u00e7et\u2019s disease with infliximab","volume":"32","author":"Sarwar H","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_4_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200307000-00003"},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05497-6"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00025"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem034"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.022"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.903"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.09.010"},{"key":"e_1_2_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30618-0"},{"key":"e_1_2_4_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000055585"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115843"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh311"},{"key":"e_1_2_4_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0346-y"},{"key":"e_1_2_4_82_1","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL\u201010 and IL\u201012 in Beh\u00e7et\u2019s disease soluble TNFR\u201075 as a biologic marker of disease activity","volume":"24","author":"Turan B","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_4_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"e_1_2_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(92)90250-R"},{"key":"e_1_2_4_85_1","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Behcet\u2019s disease","volume":"22","author":"Wechsler B","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72840-5"},{"key":"e_1_2_4_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.158840"},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.168856"},{"key":"e_1_2_4_89_1","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2008.69.10.31317"},{"key":"e_1_2_4_90_1","first-page":"1535","article-title":"Upregulation of Foxp3 expression by recombinant interferon\u2010alpha therapy in Behcet\u2019s disease","volume":"50","author":"Yang DS","year":"2009","journal-title":"ARVO"},{"key":"e_1_2_4_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002013220501"},{"key":"e_1_2_4_92_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27492010000100007"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2011.02348.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-3768.2011.02348.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T14:26:01Z","timestamp":1698675961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2011.02348.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,20]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/j.1755-3768.2011.02348.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02348.x","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,20]]},"assertion":[{"value":"2012-04-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}